Our data in BC cells, mouse models, and PDOs demonstrate that combined administration of PHGDH and LAT1 inhibitors significantly blunts the growth advantage of mutp53-bearing tumors, especially under AA limitation. This evidence concerns the gene SLC7A5 and breast cancer.